Attention-deficit/hyperactivity disorder (ADHD) and substance use disorders are inextricably intertwined. Children with ADHD are more likely than peers to develop substance use disorders. Treatment with stimulants may reduce the risk of substance use disorders, but stimulants are a class of medication with significant abuse and diversion potential. The objectives of this clinical report were to present practical strategies for reducing the risk of substance use disorders in patients with ADHD and suggestions for safe stimulant prescribing.
EPIDEMIOLOGY OF SUDS AMONG INDIVIDUALS WITH ADHD

Children and adolescents with ADHD are more likely to misuse alcohol, tobacco, and other illicit substances compared with children without ADHD. In a 2011 meta-analytic review of the prospective association of childhood ADHD and substance use, Lee et al included 27 longitudinal studies that followed up children with and without ADHD into adolescence or adulthood. The following demographic/methodologic factors did not significantly moderate the associations between childhood ADHD and substance outcomes: gender, age, race, publication year, sample source, version of the Diagnostic and Statistical Manual of Mental Disorders used to diagnose ADHD, family history of SUD, cognitive impairment, executive dysfunction, and family environment. Lee et al reported that, compared with control subjects without ADHD, children with ADHD were:

- twice as likely to have a lifetime history of nicotine use (odds ratio [OR]: 2.08, \( P < .001 \));
- nearly 3 times more likely to report nicotine dependence in adolescence/adulthood (OR: 2.82, \( P < .001 \));
- almost 2 times more likely to meet diagnostic criteria for alcohol abuse or dependence (OR: 1.74, \( P < .001 \));
- approximately 1.5 times more likely to meet criteria for marijuana use disorder (OR: 1.58, \( P = .003 \));
- twice as likely to develop cocaine abuse or dependence (OR: 2.05, \( P < .001 \)); and
- more than 2.5 times more likely to develop an SUD overall.

ADHD is associated with an earlier age at onset of substance use and a higher likelihood of use of a variety of substances. Brook et al reported that the diagnosis of ADHD poses an increased risk of SUD into adulthood; meeting criteria for a diagnosis of ADHD in adolescence is associated with developing SUDs in a subject’s 20s and 30s. Among individuals with ADHD, the number of inattention and hyperactivity/impulsivity symptoms exhibited is positively correlated with risk of substance use. Debate exists regarding whether the inattentive versus hyperactive/impulsive subtypes of ADHD confer different risk.

EXPLORING THE BIOLOGICAL AND ENVIRONMENTAL BASIS OF THE RELATIONSHIP BETWEEN ADHD AND SUD

To date, the mechanisms underlying the association between ADHD and SUDs are not completely understood, although several theories have been proposed. Impulsivity is associated with an increased risk of substance use, a prerequisite for developing an SUD. It is also possible that impulsivity and poor judgment associated with ADHD contribute to the development of SUDs. However, executive functioning deficits and increased substance use seem to be only one piece of the puzzle. In addition to difficulty with executive functioning and poor judgment, which may lead to trying substances, individuals with ADHD may also be biologically more vulnerable to developing addiction than their peers without ADHD.

Dopamine transmission is central to current models of both ADHD and SUDs. Compared with unaffected control subjects, individuals with ADHD have greater dopamine transporter density, which may result in rapid clearance and low levels of synaptic dopamine. Drugs of abuse, including cocaine, amphetamine, methamphetamine, Ecstasy, nicotine, alcohol, opiates, and marijuana, all increase synaptic dopamine concentrations, most notably in the brain’s reward center, the nucleus accumbens. Stimulant medications manage ADHD symptoms by increasing synaptic dopamine concentrations in the striatum (which includes the nucleus accumbens) via presynaptic transporters. Theoretically, some individuals with ADHD may use substances to increase synaptic dopamine concentrations as a form of self-medication. Another theory proposes a common genetic factor underlying both ADHD and risk of SUDs, although more studies are needed to further evaluate this association.

Children and adolescents with ADHD have higher rates of grade retention and school dropout than those without ADHD. These academic failures may increase an individual’s likelihood to use drugs as a means to escape anxiety about school. Academic failures may also cause changes in peer groups, placing the individual with ADHD in social settings with others who have experienced school problems and are at a higher risk of alcohol and drug use.

TREATING ADHD AND CO-OCCURRING MENTAL HEALTH DISORDERS TO REDUCE THE RISK OF SUDS

Treatment of ADHD May Reduce the Risk of SUDs

Treatment of ADHD symptoms with stimulant medication may reduce the risk of developing SUDs. Biederman et al determined that pharmacotherapy was associated with an 85% reduction in risk of SUDs in youth with ADHD. Timing of treatment matters: children with ADHD who are treated with stimulant medication at a younger age are less likely to use substances than those who have delayed onset of treatment. Behavioral therapy may also confer some protection against substance use. Findings from the Multimodal Treatment Study of Children with ADHD revealed that
behavioral interventions afforded protection from SUDs at 24 months’ post-intervention but not at 36 months. The optimal age at which to begin treatment of ADHD to decrease the risk of substance use has not been established. The American Academy of Pediatrics (AAP), in its clinical practice guidelines for ADHD, recommends treating ADHD symptoms in children 6 years and older by using both behavioral interventions and medications approved by the US Food and Drug Administration. The AAP recommends that ADHD symptoms in children as young as 4 years be treated with behavioral interventions and possibly medications. In this context, treatment of ADHD symptoms is recommended as soon as the diagnosis of ADHD is made. Symptoms of ADHD often persist into adulthood, although optimal duration of medication treatment has not been established. Maintaining children on medication while symptoms persist and monitoring for adverse effects seems to be a reasonable approach.

As noted in the AAP clinical practice guidelines for ADHD, at any point at which a clinician believes that he or she is not adequately trained or is uncertain about making a diagnosis or continuing with treatment, a referral to a pediatric or mental health subspecialist should be made. If a diagnosis of ADHD or another condition is made by a subspecialist, the primary care clinician should develop a management strategy with the subspecialist which ensures that the child will continue to receive appropriate care consistent with a medical home model wherein the primary care clinician partners with parents so that both health and mental health needs are integrated.

**Treating Co-occurring Mental Health Disorders**

Co-occurring mental health conditions are common in individuals with ADHD and are associated with increased SUD risk. Brook at al determined that conduct disorder mediated the association of ADHD and SUDs. Other studies have revealed that, even after controlling for conduct disorder, ADHD symptoms are associated with increased risk of both substance use and development of SUDs. Comorbid conditions, including depression, anxiety, and low self-esteem, have each been noted to confer increased risk of substance use in individuals with ADHD. These findings suggest that diagnosing and treating co-occurring conditions in individuals with ADHD may help to reduce the risk of developing SUDs.

**STIMULANT MEDICATIONS**

Stimulant medications are highly effective for children and adolescents in reducing the core symptoms of ADHD. The most commonly used preparations of stimulant medication are methylphenidate and amphetamine. Atomoxetine, a selective norepinephrine reuptake inhibitor, and long-acting guanfacine and clonidine, which are selective α2-adrenergic agonists, are also recommended for the management of some ADHD symptoms. However, the effect sizes (meaning likelihood of reducing ADHD symptoms compared with placebo) are lower for atomoxetine and long-acting guanfacine and clonidine than they are for the stimulant medications.

Stimulant medications are both more effective at treating ADHD symptoms and much more commonly misused than nonstimulant medications. Pediatricians are thus in a position to prescribe a medication that can reduce both ADHD symptoms and the risk of developing an SUD and simultaneously pose a risk for abuse and diversion. An understanding of the factors associated with misuse, abuse, and diversion of stimulant medication may help to guide safe use. Table 1 lists the most commonly used medications for ADHD and their suspected relative abuse potential. The terms “misuse,” “diversion,” and “abuse” are all associated with improper use of medication, but they are different phenomena with different definitions. The term misuse includes the use of medications not prescribed to the individual and using medications in ways other than prescribed. Examples of misuse include taking larger or more frequent doses than prescribed or using someone else’s medication to enhance performance. The most common reasons reported for stimulant misuse are to concentrate, study, and improve grades; “to party” and “get high”; and to experiment. Most individuals who misuse stimulant medications do so via oral administration, with intranasal insufflation (“snorting”) less common. Adolescents who report snorting medications or using stimulants to “get high” may be at highest risk of stimulant abuse and dependence. The term diversion means the transfer of medication from the person to whom it is prescribed to a person for whom it is not prescribed. The term substance abuse was used in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, to refer to use associated with problems or risk that interfere with functioning. The term addiction refers to loss of control or compulsive use of a substance. In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), diagnostic terms were changed to SUD, mild/moderate/severe, depending on the number of positive criteria. Even though they are not formal diagnoses, the terms substance abuse and addiction will likely remain in the lexicon and retain their meaning for some time, particularly in reference to prescription medications.
Misuse of Stimulant Medications

Misuse and diversion of stimulant medications are more widespread problems than abuse or addiction. Wilens et al conducted a systematic review of the literature examining misuse and diversion of prescription ADHD medications. Of the 21 studies reviewed, rates of past-year non-prescribed stimulant use ranged from 5% to 9% in grade school and high school children and from 5% to 35% in college-aged individuals. In a large public university in the mid-Atlantic region, Arria et al found that 18% of students who were not prescribed stimulants engaged in nonmedical stimulant use, more than one-quarter (26.7%) of students with diagnosed ADHD reported having used more medications than prescribed, and 15.6% reported using someone else’s prescription stimulants in their lifetime.

Table 1: List of Most Commonly Used Medications for ADHD With Suspected Relative Abuse Potential

<table>
<thead>
<tr>
<th>Stimulant Status</th>
<th>Medication Type</th>
<th>US Trade Namea</th>
<th>Suspected Relative Abuse Potentialb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-acting/immediate release</td>
<td>Methylphenidate</td>
<td>Ritalina</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td>Methylinia</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dexamethylphenidate</td>
<td>Focalina</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td>Amphetamine-dextroamphetamine</td>
<td>Adderalla</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td>Dextroamphetamine</td>
<td>Dexedrina</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td>Daytrana patch</td>
<td>Concerta</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Metadate CD</td>
<td>Metadate ERa</td>
<td>Medium</td>
</tr>
<tr>
<td></td>
<td>Ritalin LAa</td>
<td>Ritalin SRa</td>
<td>Medium</td>
</tr>
<tr>
<td></td>
<td>Methylsulfone</td>
<td>Daytrana patch</td>
<td>Medium</td>
</tr>
<tr>
<td></td>
<td>Dextroamphetamine</td>
<td>DextroStata</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td>ProCentra</td>
<td>ProCentra</td>
<td>High</td>
</tr>
<tr>
<td>LA/ER</td>
<td>Methylphenidate</td>
<td>Metadate CD</td>
<td>Medium</td>
</tr>
<tr>
<td></td>
<td>Metadate ERa</td>
<td>Metadate ERa</td>
<td>Medium</td>
</tr>
<tr>
<td></td>
<td>Ritalin LAa</td>
<td>Ritalin SRa</td>
<td>Medium</td>
</tr>
<tr>
<td></td>
<td>Methylsulfone</td>
<td>Methylsulfone</td>
<td>Medium</td>
</tr>
<tr>
<td></td>
<td>Dextroamphetamine</td>
<td>DextroStata</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td>ProCentra</td>
<td>ProCentra</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td>Daytrana patch</td>
<td>Daytrana patch</td>
<td>Medium</td>
</tr>
<tr>
<td></td>
<td>Concerta</td>
<td>Concerta</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Quillivant XR</td>
<td>Quillivant XR</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Dextroamphetamine</td>
<td>DextroStat</td>
<td>Medium</td>
</tr>
<tr>
<td></td>
<td>Dextroamphetamine</td>
<td>DextroStat</td>
<td>Medium</td>
</tr>
<tr>
<td>Nonstimulants</td>
<td>α2-adrenergic agonists</td>
<td>Guanfacine</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Clonidine</td>
<td>Clonidine</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Atomoxetine</td>
<td>Atomoxetine</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Lisdexamfetamine</td>
<td>Vyvanse</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Concerta</td>
<td>Concerta</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Quillivant XR</td>
<td>Quillivant XR</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Dextroamphetamine</td>
<td>DextroStat</td>
<td>Medium</td>
</tr>
<tr>
<td></td>
<td>Dextroamphetamine</td>
<td>DextroStat</td>
<td>Medium</td>
</tr>
<tr>
<td></td>
<td>Lisdexamfetamine</td>
<td>Vyvanse</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Concerta</td>
<td>Concerta</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Quillivant XR</td>
<td>Quillivant XR</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Dextroamphetamine</td>
<td>DextroStat</td>
<td>Medium</td>
</tr>
<tr>
<td></td>
<td>Dextroamphetamine</td>
<td>DextroStat</td>
<td>Medium</td>
</tr>
<tr>
<td></td>
<td>Lisdexamfetamine</td>
<td>Vyvanse</td>
<td>Low</td>
</tr>
</tbody>
</table>

CR, controlled release; ER, extended release; LA, long acting; XR, extended release; SR, sustained release.
a Indicates that generic formulation is available.
b Relative abuse potential is suspected based on length of action and formulation of medication.

Abuse of Stimulant Medications

Methylphenidate and amphetamine both have known abuse potential, although there is little evidence that these drugs are widely abused by the patients to whom they are prescribed, and evidence for abuse potential among children and adolescents is limited. “Subjective effect” (ie, how much a person likes a drug, achieves euphoria, experiences reinforcement with use) is an important factor considered in determining abuse potential of a substance. Among individuals without ADHD, both methylphenidate and amphetamine produce significant subjective effects; amphetamine is nearly twice as potent as methylphenidate at equivalent doses. Research performed in the 1970s revealed that stimulants do not reliably produce these subjective effects in individuals with ADHD. Fredericks and Kollins found that individuals with ADHD displayed a higher preference for methylphenidate compared with placebo, although other measures of abuse potential, specifically participant-rated effects of methylphenidate on mood, were not elevated. Thus, the preference for methylphenidate may reflect its therapeutic efficacy rather than abuse potential.
SAFE STIMULANT-PRESCRIBING PRACTICES

In light of the high risk of SUDs among individuals with ADHD, pediatricians should seek to accurately diagnose ADHD and treat symptoms appropriately. Several precautions may help to reduce stimulant misuse, abuse, and diversion.

Before Prescribing, Confirm a Diagnosis of ADHD

Inattention is multifactorial. Many children or adolescents who are depressed, anxious, neglected, or having academic difficulty because of a learning disorder may present as inattentive. ADHD is a primary disorder of attention. According to the diagnostic criteria for ADHD in the DSM-5, ADHD symptoms must be present during childhood; thus, particular caution is warranted before making a new diagnosis of ADHD, especially in an adolescent. Although it is possible that symptoms in childhood were unnoticed, adolescents sometimes attempt to get a stimulant prescription by feigning symptoms of ADHD. The diagnosis of ADHD is made clinically in an individual who fulfills the criteria for ADHD listed in the DSM-5. Standardized tools, such as parent- and teacher-completed ADHD rating scales, assist in making a diagnosis and should be used in the assessment. A thorough history, review of medical and school records, and a collateral parent interview may all help confirm a correct diagnosis. The criteria used for diagnosing ADHD and any history or evaluations that were made to rule out other conditions that might be confused with ADHD (eg, sleep disturbances, other learning disabilities, thyroid dysfunction) should be recorded in the patient’s medical record. The AAP’s Clinical Practice Guideline for ADHD provides specific guidance about diagnosis and management.

Screen Older Children and Adolescents for Use of Alcohol, Marijuana, and Other Drugs

The AAP recommends screening, brief intervention, and referral to treatment as part of routine health care for older children and adolescents. This recommendation is particularly important for adolescents with ADHD, who are more likely to use substances and to develop an SUD than their peers. Adolescents with ADHD who use alcohol, marijuana, or other substances are also more likely to divert stimulant medication and thus require increased attention and monitoring by their prescriber.

The AAP policy statement titled “Substance Use: Screening, Brief Intervention, and Referral to Treatment for Pediatricians” provides a complete review of recommended screening tools and brief interventions for adolescent substance use. The AAP currently recommends the 3 “opening questions” associated with the CRAFFT tool (see the following text) to detect past-year substance use. Although currently an active area of National Institutes of Health–funded research, these questions have not been validated to date, and it is not known whether the “other drugs” question is sensitive enough for identifying misuse or abuse of prescription medications. An additional question (eg, “Have you ever used someone else’s prescribed medication?”) may be warranted to identify misuse, particularly before prescribing a stimulant medication for the first time.

“Opening questions” to identify past-year substance use:
In the past year, have you:
1. Had a drink with alcohol in it?
2. Used marijuana?
3. Used any other substance to get high?

Provide Anticipatory Guidance

Anticipatory guidance regarding proper use of stimulant medications should be part of every patient encounter in which medications for ADHD are discussed. Table 2 lists points that should be included in this discussion. The pediatrician should discuss that medications should only be taken as prescribed by the physician, even with very young children, in a developmentally appropriate manner. As children enter the upper elementary school years, the conversation should evolve to include discussion about the proper use of medication. Children and parents should be aware of the risk for misuse, diversion, and abuse. Children should understand that trading or selling stimulant medication is illegal. Children who live in areas of high-crime rates should have a concrete, realistic safety plan for managing their medication. For children who are 12 years and older, the discussion should also include information about careful transitioning of administration of medication. Although the child should not be pushed to start self-administering medication, having this discussion earlier with the family can alert them that transition of medication management from caregiver to child should be a gradual and carefully monitored one so that when the child is developmentally ready to assume more responsibility of medication management, there is a plan in place to ensure that the transition is safe.

Document Prescription Records

Stimulant medication is a Drug Enforcement Administration Class II controlled substance. Every prescriber must document and monitor the prescribing of stimulant medications. Requests for early refills should be explored and carefully documented to...
Risk of misuse, diversion, and abuse

Illicit substance use often results in a context of active SUD. Prescribing medications for ADHD for the same patient requires reevaluation after a period of abstinence may be warranted. Adolescents who have both previously diagnosed ADHD and an active SUD may be difficult to monitor because symptoms of substance use may be indistinguishable from ADHD symptoms. In general, an active SUD should be treated (usually via referral to a mental health counselor or addiction specialist) before beginning medication to treat ADHD. However, for patients with well-documented ADHD that predates the onset of substance use, it may be reasonable to treat both disorders concurrently. Consultation with a psychiatrist or addiction specialist when managing complex patients is suggested. When considering which ADHD medication to prescribe to a patient with a co-occurring SUD, a careful risk/benefit assessment must be conducted. If the patient is currently abusing prescription stimulants or there is a clear indication that the patient would sell or divert stimulant medication, it may be best to start with a long-acting stimulant medication with low risk of misuse or diversion. Long-acting preparations, especially those with an osmotic controlled-release oral delivery system such as Concerta, have lesser likelihood of misuse or diversion. It is also reasonable to consider use of a non-stimulant preparation, even though nonstimulant medications are less efficacious than stimulants. The prodrug formulation of dextroamphetamine, lisdexamfetamine, has a lower abuse potential than other stimulants and thus may be considered. However, physicians should be aware that any psychoactive medication can be misused. As for all patients, it is important to carefully monitor medication adherence.

A special circumstance occurs when a pediatrician prescribes stimulant medications for college students and older patients living away from home. A treatment plan should document how medication will be prescribed and how frequently the patient is expected to return for follow-up visits with the pediatrician. Medication administration by a student health staff member or keeping medications in a small medication safe may reduce diversion or theft. Follow-up visits should include self-report of medication efficacy, adverse effects (appetite, abdominal symptoms, headaches, and sleep disturbance) and screening for medication misuse, abuse, or diversion. The patient’s responses should be documented in the medical record. Reports or suggestions of new physical or mental health symptoms require reevaluation.

**Summary**

ADHD is a common neurobehavioral disorder of childhood, and individuals with ADHD are more likely to misuse alcohol, tobacco, and other illicit substances, hyperactivity, and/or impulsivity, making a new diagnosis of ADHD difficult or impossible to distinguish from symptoms related to ongoing substance use. In these cases, reevaluation after a period of abstinence may be warranted. Adolescents who have both previously diagnosed ADHD and an active SUD may be difficult to monitor because...
substances compared with children and adolescents without ADHD. Individuals with ADHD and co-occurring mental health conditions, such as disruptive behavior disorders or depression, are at even higher risk of developing SUDs. Appropriate treatment of ADHD symptoms with medication and behavior therapy may reduce the risk of development of SUDs. Primary care providers should seek to identify and treat ADHD to prevent the development of SUDs. Furthermore, the recommended first-line medication therapy for ADHD is stimulant medications, which themselves pose a risk of misuse, diversion, and abuse. Therefore, an important part of ADHD treatment and stimulant medication management includes screening for SUDs and providing anticipatory guidance around the appropriate and safe use of stimulant medications. Individuals with co-occurring ADHD and active SUDs require a careful, individual risk/benefit assessment regarding the safety of prescribing a stimulant medication. Longer-acting preparations of stimulant medication, the prodrug formulation of dextroamphetamine, and non-stimulant medications for ADHD all have lower abuse potential than short-acting preparations of stimulant medication and, thus, their use should be strongly considered if there is a high risk of misuse, diversion, or abuse of stimulant medications.

REFERENCES


LEAD AUTHORS
Elizabeth Harstad, MD, MPH, FAAP
Sharon Levy, MD, MPH, FAAP

COMMITTEE ON SUBSTANCE ABUSE, 2013–2014
Sharon Levy, MD, MPH, FAAP, Chairperson
Seth D. Ammerman, MD, FAAP
Pamela K. Gonzalez, MD, FAAP
Sheryl A. Ryan, MD, FAAP
Lorena M. Siqueira, MD, MSPH, FAAP
Vincent C. Smith, MD, MPH, FAAP

LIAISONS
Vivian B. Faden, PhD – National Institute of Alcohol Abuse and Alcoholism
Gregory Tau, MD, PhD – American Academy of Child and Adolescent Psychiatry

STAFF
Renee Jarrett, MPH
James Baumberger, MPP
Katie Crumley, MPP

FROM THE AMERICAN ACADEMY OF PEDIATRICS

PEDIATRICS Volume 134, Number 1, July 2014
Downloaded from by guest on April 7, 2017


53. Selik J, Bond GR, Ho M. Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. Pediatrics. 2008;124(3):875–880


59. Kollins SH. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD). Am J Addict. 2007;16(suppl 1):35–42; quiz 43–44


74. Levy SJ, Kokotailo PK; Committee on Substance Abuse. Substance use screening, brief intervention, and referral to treatment for pediatricians. Pediatrics. 2011;128(5). Available at: www.pediatrics.org/cgi/content/full/128/5/e1330


### Updated Information & Services

Including high resolution figures, can be found at:
/content/134/1/e293.full.html

### References

This article cites 69 articles, 8 of which can be accessed free at:
/content/134/1/e293.full.html#ref-list-1

### Citations

This article has been cited by 2 HighWire-hosted articles:
/content/134/1/e293.full.html#related-urls

### Post-Publication Peer Reviews (P³Rs)

3 P³Rs have been posted to this article
/cgi/eletters/134/1/e293

### Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):
- Committee on Substance Use and Prevention
  /cgi/collection/committee_on_substance_abuse
- Substance Abuse
  /cgi/collection/substance_abuse_sub

### Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
/site/misc/Permissions.xhtml

### Reprints

Information about ordering reprints can be found online:
/site/misc/reprints.xhtml
Attention-Deficit/Hyperactivity Disorder and Substance Abuse
Elizabeth Harstad, Sharon Levy and COMMITTEE ON SUBSTANCE ABUSE
Pediatrics 2014;134;e293; originally published online June 30, 2014;
DOI: 10.1542/peds.2014-0992

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/134/1/e293.full.html